Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/26362
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRees, Matthew J-
dc.contributor.authorWu, Simon-
dc.contributor.authorMokoonlall, Mridula-
dc.contributor.authorDix, Caroline H K-
dc.contributor.authorBryant, Christian E-
dc.contributor.authorD'Rozario, James-
dc.contributor.authorSchwarer, Anthony P-
dc.contributor.authorGrigg, Andrew P-
dc.contributor.authorTiong, Ing S-
dc.date2021-04-26-
dc.date.accessioned2021-05-03T05:19:45Z-
dc.date.available2021-05-03T05:19:45Z-
dc.date.issued2021-04-26-
dc.identifier.citationLeukemia & Lymphoma 2021; online first: 26 Aprilen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/26362-
dc.language.isoeng
dc.titleThe real-world tolerability and efficacy of asparaginase in adults aged 40 years and older with Philadelphia-negative acute lymphoblastic leukemia.en
dc.typeJournal Articleen
dc.identifier.journaltitleLeukemia & Lymphomaen
dc.identifier.affiliationDepartment of Clinical Haematology, Eastern Health, Melbourne, Australiaen
dc.identifier.affiliationClinical Haematologyen
dc.identifier.affiliationDepartment of Clinical Haematology, Canberra Hospital, Canberra, Australiaen
dc.identifier.affiliationInstitute of Haematology, Royal Prince Alfred Hospital, Sydney, Australiaen
dc.identifier.doi10.1080/10428194.2021.1919666en
dc.type.contentTexten
dc.identifier.orcid0000-0001-8360-2952en
dc.identifier.pubmedid33899667
Appears in Collections:Journal articles
Show simple item record

Page view(s)

22
checked on Jul 2, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.